Nanobiotix SA (EUR)
NANO
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range6.50 | 6.70
52-Wk Range- | -
Last Close6.50
Mkt Cap (m)169.15
Dividend yield-
ISINFR0011341205
Volume61,632.00
Exchange VenuePAR

Company Profile

Nanobiotix SA is engaged in the development of NanoXray, a pipeline of patented products, which are based on a physical mechanism of action. It develops tools for cancer, which utilize a physical mode of action at the cellular level of the cancer cell.

Key Information
Price/Earning-
Price/Book0.00
Price/Sales2,152.03
P/CF-
Rev Growth (3 year avg)-64.79
EPS Growth (3 year avg)-
Operating Margin % -68,792.65
Net Margin %-74,875.00
Return on Equity-825.60
Debt/Equity-

Documents

Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

http://www.nanobiotix.com

Financials

Income Statement
EUR201420152016201720182019
Revenue (m)0.970.271.560.250.120.07
Operating Income (m)-9.62-17.14-21.85-25.27-9.17-46.78
Net Income (m)-9.56-17.00-21.88-26.14-30.35-50.92
Basic EPS-0.74-1.20-1.43-1.50-1.55-2.35
Avg. Diluted Shares Outstanding (m)12.8714.1415.2817.4819.6321.63
Balance Sheet
EUR201420152016201720182019
Current Assets (m)35.5022.9526.8953.1142.6546.13
Non Current Assets (m)1.553.473.514.363.5410.08
Total Assets (m)37.0526.4230.4057.4746.2056.21
Current Liabilities (m)4.427.108.259.3511.6014.35
Total Liabilities (m)------
Total Equity (m)30.3215.6117.4043.9214.24-1.91
Cash Flows
EUR201420152016201720182019
Operating Cash Flows (m)-8.56-16.82-18.28-21.03-25.99-41.17
Capital Expenditure (m)-----0.51-1.44
Figures are quoted in EUR unless stated otherwise
-
No change
6.50
Last Price